title: Translational research in immune and inflammatory diseases; what are the challenges, expected advances, and innovative therapies?
abstract: Despite very different aetiologies and clinical expressions, advancing knowledge in the physiopathology and treatment of immune and inflammatory diseases (IID) prompts us to consider them as a whole. These are chronic, often incapacitating and painful illnesses that progress and destroy organs. Management by discipline too often leads to erroneous diagnoses and sometimes inappropriate treatment. More integrated translational research would further understanding of the complex relationships between cytokines and organ damage, which vary with the conditions and patients, making it possible to develop new biomarkers and personalize treatment. The research in France has very many strengths but its organization is fragmented. Better coordinated research into IID, which could be based on creating a strategic valorization field (domaine de valorisation stratégique, DVS) and thematic multi-organization institute (Institut thématique multi-organismes ITMO), would advance patient management.
authors.affiliation: Laboratoire UCB, Colombes, France.
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Joubert
authors.affiliation: CHRU, Strasbourg, France.
authors.forename: Jacques-Eric
authors.initials: JE
authors.lastname: Gottenberg
authors.affiliation: Université François-Rabelais de Tours, CNRS, GICC UMR 7292, CHRU de Tours, France.
authors.forename: Gilles
authors.initials: G
authors.lastname: Paintaud
authors.affiliation: Laboratoire Lilly, Nogent sur Marne, France.
authors.forename: Béatrice
authors.initials: B
authors.lastname: Augendre-Ferrante
authors.affiliation: Inserm Transfert, Paris, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Cans
authors.affiliation: Laboratoire Merck, Lyon, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Cellier
authors.affiliation: Laboratoire Pfizer, Paris, France.
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Chevalier
authors.affiliation: LEEM, Paris, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Diaz
authors.affiliation: Laboratoire CSL Behring, Paris, France.
authors.forename: Jamila
authors.initials: J
authors.lastname: Filipecki
authors.affiliation: Hôpital Foch, Suresnes, France.
authors.forename: Jean-Emmanuel
authors.initials: JE
authors.lastname: Kahn
authors.affiliation: Inserm Transfert, Paris, France.
authors.forename: Johan
authors.initials: J
authors.lastname: Le Men
authors.affiliation: Université François Rabelais; CHRU de Tours, Tours, France.
authors.forename: Denis
authors.initials: D
authors.lastname: Mulleman
authors.affiliation: LFB Biotechnologies, Les Ulis, France.
authors.forename: Rémi
authors.initials: R
authors.lastname: Urbain
authors.affiliation: Agence nationale de la recherche, Paris, France.
authors.forename: Daniel
authors.initials: D
authors.lastname: Vasmant
mesh_terms: D000047:Academies and Institutes; D003299:Cooperative Behavior; D005544:Forecasting; D005602:France; D019981:Health Care Sector; D006761:Hospitals; D006801:Humans; D007154:Immune System Diseases / Q000145:classification / Q000503:physiopathology / Q000628:therapy*; D007249:Inflammation / Q000145:classification / Q000503:physiopathology / Q000628:therapy*; D038622:Internationality; D007753:Laboratories; D018581:Technology Transfer; D035703:Therapies, Investigational; D057170:Translational Research, Biomedical / Q000639:trends*